lower pharmaceut distributor moat trend
fve across board
page full analyst note apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
smallest youngest three lead
pharmaceut medic distributor
employe across own oper facil leas
oper facil around world cardin health
address comprehens sourc distribut need
manufactur provid global scale sheer
pharmaceut volum enabl compani negoti
competit price manufactur pharmaci
provid pbm effici provid access vast
portfolio drug core busi roughli revenu
focus pharmaceut distribut balanc
revenu contract manufactur distribut medic
suppli handl roughli one third drug
sold unit state compani oper effici
highli regul environ provid insul
drug price drug mix gener versu brand drug volum
larg drive core busi pharmaceut distribut
servic deceler pharmaceut drug growth due
slower brand drug inflat shift mix favor gener
drug lower price point slower introduct blockbust
drug increas provid negoti leverag custom
concentr put oper margin pressur
howev high cost pharmaceut drug off-set
declin introduct brand drug overal
oper margin rel displac brand drug like
lower similar two largest distributor compani
grown signific size regular acquisit
like necessari supplement growth order off-set
slower growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
cardin health third-largest global logist provid engag
wholesal pharmaceut medic product similar two
peer compani evolv time becom entrench
sourc distribut brand-nam gener pharmaceut
relat servic hospit healthcar system pharmaci
ambulatori surgeri center clinic laboratori physician offic
acquisit cardin health abil manufactur
commod product certain medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trend fve across board apr
reassess pharmaceut distribut
segment light evolv competit regulatori
environ base continu declin pharmaceut
spend growth extern shock threat lower
moat rate
wide narrow neg moat
trend also reduc fair valu estim
despit stabl foothold oligopoli market
three compani handl market role
pharmaceut distributor continu evolv
increasingli competit highli regul environ
scale regulatori requir provid insul
maintain share gener market return
competit pressur continu build declin
reimburs healthcar consolid declin
pharmaceut revenu growth declin due slower
inflat shift revenu mix consist overal
pharmaceut spend trend expect revenu growth
pharmaceut distributor declin overal
growth pharmaceut spend declin
double-digit growth past three
four year oper margin industri
declin lower level like persist
signific declin pharmaceut market growth
caus distributor seek altern growth
channel acquisit entri new
area outsid core compet costli
extern shock elimin rebat
increas price transpar would diminish
pharmaceut distributor valu negoti
transpar price provid manufactur
would less like need middleman negoti rate
would give custom leverag renegoti
distribut contract deterior distributor
lower fair valu estim cardin health
per share impli fiscal
enterpris adjust ev/ebitda multipl time
free cash flow yield dividend yield
revenu driver price volum mix
disclos made sever assumpt project
industri growth except potenti extern
market shock anticip market share shift
dramat near term result anticip
overal annual top-lin growth roughli larg
benefit growth specialti pipelin
increas number therapi age popul
brand drug
compon growth varieti factor includ
slower growth introduct new
drug neg less extent gener deflat
lower spend hepat prescript opioid
factor net anticip industri revenu
growth roughli similar industri
rang accord iqvia express script
consist overal pharmaceut spend trend
expect revenu grow declin
approxim compound-annual-growth-rate past three year
histor revenu growth continu lumpi due
mix drug introduct inflat acquisit
overal drug volum skew toward gener similar
industri averag roughli howev lower
gener price point would translat roughli half
optumrx top five custom account
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
regulatori chang believ limit upsid
base scenario per share
bull-cas fair valu estim per share
scenario revenu growth basi
point higher base scenario result slightli
bear-cas fair valu estim per share
oper margin project declin basi
point due increas custom
negoti leverag signific chang
legisl regulatori environ extern shock
factor would increas uncertainti
uncertainti rate pharmaceut
distributor stand medium due competit
environ potenti extern shock includ
legisl chang increas price transpar
potenti entranc new competitor
cardin assign narrow-moat rate aris
cost advantag
cardin health
effect oper oligopoli entrench
within custom base three lead distributor
similar differ slightli largest
pharmaceut distributor certain global contract
manufactur capabl vertic integr
provid retail pharmaci chain canada
europ closest pure-play
pharmaceut distributor platform base insid
close provid retail pharmaci cardin
smallest three lead pharmaci
distributor
approxim total consolid
past three four year oper margin
industri declin oper margin cardin
declin
model oper margin declin
fiscal next five year declin
revenu anticip continu pressur
pharmaceut distribut headwind
ration medic devic oper
part valuat framework addit
base-cas dcf model bull case bear case
valuat scenario critic debat
surround compani abil entrench exist
partnership manufactur
negoti provid
financ
inventori manag servic
provid negoti provid specialti drug distribut
base current high level custom concentr
increas competit environ potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
manufactur capabl medic devic
compani invest infrastructur provid
abil navig highli regul drug market scale
also enabl compani negoti behalf
provid retail pharmaci requir infrastructur
regulatori hurdl requir logist manag
insul compani new entrant
pyxi medic product manufactur distributor
divis baxter healthcar medic devic
compani divis johnson johnson medtron
addit sever smaller acquisit also unlik
cardin
certain contract manufactur acquisit
distributor world along
repres market
time role pharmaceut distributor evolv
increas number new therapi format
govern regulatori organ regulatori
requir
licensur manufactur retail
pharmaci pharmaceut distributor
evolut compani continu invest
physic infrastructur provid logist support
highli effici manner compani scale also
provid abil negoti lower price drug
manufactur across comprehens portfolio gener
brand specialti drug behalf provid acut
hospit clinic mail pharmaci retail
complianc certain financ function provid
manufactur support commerci
infrastructur escal past decad
cardin health invest nearli billion
capit expenditur billion acquisit
billion order strengthen posit matur
autom
cardin health initi found food
focus wholesal drug
manufactur acquisit bailey drug later
decad sinc time compani made seri
acquisit rang autom pill dispens
product distribut limit transport asset
commod natur compani distribut servic
reflect low oper margin despit
low margin compani histor gener roic
larg due scale growth driven strong
drug price inflat increas therapi
current lack price transpar signific
variat list invoic price day day
price volatil regulatori complianc recal
provid retail pharmaci
infrastructur quickli manag avail inform
negoti competit price manufactur
cardin healthss volum also provid abil
lower price drug manufactur
increment scale compani abil provid
assist inventori manag complianc
financ convers compani also support
commerci new drug deliveri product
secur moat scale
uncertain drug price environ grow
custom leverag limit moat narrow recent
howev pharmaceut revenu declin
slower inflat shift revenu mix increas
gener versu brand drug meanwhil margin
declin like part due increas negoti
leverag custom driven healthcar provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
area outsid core compet proven costli
specif opportunist enter
medic devic busi acquisit cordi
sinc acquisit compani ration
product offer exit roughli countri cardin
continu expand new area maintain
lead posit off-set declin core busi
execut regulatori risk increas concern
addit extern shock highli contest
reduct rebat increas price transpar
would diminish pharmaceut distributor
valu negoti transpar price
provid manufactur would less like need middl
man negoti rate would give custom
leverag renegoti distribut contract
amazon may immedi threat next sever
year discount altogeth
compani signific resourc appear
method gather expertis effect compet
healthcar distribut amazon signific inventori
manag expertis quietli accumul
core piec need compet pharmaceut
distributor includ pillpak state distributor licens
joint ventur jp morgan berkshir
consolid top five custom
repres revenu oper margin declin
exacerb ratino product
intern locat medic devic acquisit
factor weigh roic trend like
persist long term view
despit insul provid compani amass
physic infrastructur complex regulatori
environ overal market pressur continu build
larg due declin reimburs healthcar
consolid deceler growth
overal
pressur manufactur provid press focu
cost contain result pharmaceut
distribut client activ solicit bid
negoti better price commod servic
distributor also includ client gener sourc
joint ventur red oak sourc cardin
walgreen boot allianc walgreen
claruson
healthcar consolid also increas
concentr pharmaceut distribut custom
top five cardin custom repres
roughli revenu market pressur
leverag pharmaceut distributor
custom
largest contributor
deterior overal industri margin
declin consecut last sever year even
provid manufactur appear test direct
altern may limit could also
like
signific declin pharmaceut market
growth caus distributor seek altern
channel acquisit entri new
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
key drug distributor handl
third pharmaceut distribut market
compani infrastructur provid scale abil
effect negoti price provid
inventori
oth compani servic enabl provid
manufactur focu core busi
outsourc logist drug highli
requir high sunk cost low oper margin
provid barrier entri highli matur market
leverag
declin reimburs matur market could
limit futur growth put pressur profit
compani continu make acquisit
outsid core compet seek altern
channel growth execut regulatori risk
oextern shock potenti legisl action
increas drug price transpar entranc
disrupt competitor could disrupt current
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ cardin health enjoy posit solid
financi strength aris strong balanc sheet
posit matur market fiscal
compani billion cash equival off-set
billion debt debt capit ratio gross
leverag time adjust ebitda free cash flow
gener million billion fiscal
exclud acquisit respect compar
lead pharmaceut distributor cardin
disciplin acquisit dividend strategi
compani regularli complet acquisit seek new
channel fuel growth manag spent roughli
billion averag acquisit three
fiscal year repres doubl histor trend
annual common stock dividend averag million
past year acceler million
fiscal dividend yield
repurchas billion worth stock fiscal
fiscal million buyback fiscal
manag roughli billion remain
share repurchas author believ compani
continu repurchas share exist
author beyond
compani oper matur oligopoli loss
regulatori chang entrant new competitor
signific resourc overal market dynam could
reduc abil negoti drug manufactur
and/or custom continu pressur drug price
pose risk compani includ deflat gener
drug price increas gener mix slower growth
pharmaci pipelin lower spend hepat
opioid risk could eman propos govern
rule seek increas transpar drug price
elimin rebat pbm propos regulatori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
chang would reduc cost drug current
pass-through revenu basi pharmaci
wholesal compens although pharmaci
distributor would opportun negoti
drugmak provid uncertainti abil
negoti industri rate paid current
increas transpar continu consolid
retail pharmaci could impact compani abil
negoti lower price cornerston servic
render compani although potenti threat
new competitor immin amazon compani
signific inventori manag expertis
quietli accumul core piec need compet
pharmaceut distributor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
scott barnhart presid global manufactur
suppli chain join compani last year
presid global suppli chain group purchas
organ respons
suppli chain procur global countri
compani oper profession servic facil
busi prior join barnhart respons
intern suppli chain manufactur
conagra food held rang role span
london-bas diageo plc lead custom servic
plan manufactur procur distributor
oper north america latin america
move corpor posit suppli chain
inform technolog consult pricewaterhousecoop
steve blazejewski presid medic solut
medic product suppli chain servic hospit
laboratori physician offic surgeri center
site care blazejewski join august
compani acquir patient
recoveri busi instrument facilit
purchas signific impact
success integr prior join
compani blazejewski senior vice presid
presid global patient monitor recoveri pmr
busi blazejewski nearli year sale
market execut leadership experi within
medic devic industri tenur patient
recoveri busi evolv root sherwood
medic chang tyco healthcar covidien
craig cowman execut vice presid global sourc
manag strateg sourc supplier manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
compani also held executive-level
commerci clinic role sunesi corpor
dendreon corpor imclon incorpor abraxi
overal leader season divers
background pharmaceut distribut see
enterprisewid capac lead team
respons sourc pharmaceut medic
product across nation brand cardin brand
well raw materi indirect good prior assum
role cowman serv compani senior vice
presid strateg sourc product manag
respons develop
deploy cardin health brand gener
consum health sourc price sell strategi
pharmaceut segment cowman
year develop
wide rang manag experi perspect
varieti area within cardin health includ
market sale telesal purchas
victor crawford chief execut offic
pharmaceut segment segment
distribut brand gener pharmaceut specialti
pharmaceut over-the-count healthcar
consum product crawford came
wide rang experi world
respect compani recent role
chief oper offic healthcar
educ busi dine join
crawford serv presid field oper
pepsi-cola beverag compani guid field leadership
team canada mexico initi join
pepsi-cola bottl compani work
varieti role financ sale appoint
vice presid gener manag greater
chicago divis pepsi-cola gener bottler inc
depinto presid cardin health specialti
solut one fastest-grow busi cardin
depinto spent past year focus
commerci specialti drug market past role
includ sale market leadership posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
trend fve across board apr
reassess pharmaceut distribut
segment light evolv competit regulatori
environ base continu declin pharmaceut
spend growth extern shock threat lower
moat rate
wide narrow neg moat
trend also reduc fair valu estim
despit stabl foothold oligopoli market
three compani handl market role
pharmaceut distributor continu evolv
increasingli competit highli regul environ
scale regulatori requir provid insul
maintain share gener market return
competit pressur continu build declin
reimburs healthcar consolid declin
pharmaceut revenu growth declin due slower
inflat shift revenu mix consist overal
pharmaceut spend trend expect revenu growth
pharmaceut distributor declin overal
growth pharmaceut spend declin
double-digit growth past three
four year oper margin industri
declin lower level like persist
signific declin pharmaceut market growth
caus distributor seek altern growth
channel acquisit entri new
area outsid core compet costli
extern shock elimin rebat
increas price transpar would diminish
pharmaceut distributor valu negoti
transpar price provid manufactur
would less like need middleman negoti rate
would give custom leverag renegoti
distribut contract deterior distributor
strong volum cardin off-set weaker
report quarterli result exceed
expect driven strong volum growth exist
pharmaci distribut client expect major
chang fair valu estim base
out-performance volum strong weaker
price off-set volum strength extent still strong
revenu carri day drove earn upsid rel
expect
follow strong result
manag rais full-year guidanc share
roughli feb seem appropri given
stronger-than-expect result result reinforc belief
scale matter healthcar distribut
maintain wide moat rate
revenu expect grow midsingl digit
full fiscal year despit strong upsid quarterli
result guidanc increas
prior guidanc would prefer
manag rais guidanc believ
conserv outlook prudent leav path
continu upsid throughout year manag
indic good traction cost-sav initi
expect exceed annual save million
fiscal million fiscal headwind
standpoint potenti chang rebat regul
pend new york opioid assess appeal rule
fiscal second quarter revenu grew year
year billion normal earn per share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
declin year year pharmaceut
distribut revenu increas driven improv
brand volum better-than-expect growth
specialti pharmaceut slightli off-set
continu headwind gener medic revenu
declin larg due divestitur china
distribut navihealth busi also oper
margin declin last year base
cardin report mix quarter posit long-term
cardin report mix quarter revenu grew
robust clip profit continu pressur
environ believ need sourc deliv
drug cost effect effici manner remain
posit fundament drug distributor dynam
form strong foundat cardin
competit posit view core drug
wholes oper need drug
manufactur retail pharmaci matter
market dynam shift accordingli reiter
wide-moat rate fair valu estim
cardin manag reiter guidanc year
confid expect incorpor conserv
outlook find encourag develop
point continu stabil oper gener
deflat moder brand inflat remain
expect trajectori manag state guidanc
incorpor scenario brand inflat could fall
basi point current expect
howev team state feel highli confid
inflat expect given convers
firm also reorgan oper manag
state everyth tabl part
reorgan includ firm refocus much
manageri bandwidth asset
build effici stabil core
pharmaceut wholesal segment major chang
firm previou strategi expand busi
portfolio global reach applaud new
manag team strategi model
modest profit improv segment forecast
oper margin expand basi point
end explicit forecast period believ
reflect conserv outlook incorpor greater
infrastructur effici modest price spread less
variabl tie brand price
ceo mike kaufman state earn call
process revamp firm busi refocus
effort process improv continu well
fiscal year believ strategi posit
long-term given greater focu optim drug
wholes oper expand
specialti
pharmaceut oper perspect
effort ultim build signific sharehold valu
beyond fiscal cardin posit critic cogs
within global pharmaceut suppli chain
dynam provid opportun produc signific
econom profit long-term thu current
discount firm stock price present opportun
investor long-term time horizon wide moat
busi signific discount
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end june
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
